Crizotinib is a kinase inhibitor indicated
for the treatment of patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or
ROS 1 positive. Crizotinib is the first FDA-approved biomarker-driven therapy
for both ALK positive and ROS1-positive metastatic NSCLC. It is the only FDA
approved drug for ROS 1 positive NSCLC.
Indication: CRIZONIX i is indicated for the
first-line treatment of adults with ALK-positive advanced NSCLC and for the
treatment of adults with previously treated ALK-positive advanced NSCLC &
ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor
tyrosine kinase) inhibitor.
||Formulation & Strength
||Capsule ( 250 mg )